Navigation Links
ENMD in Medical News

EntreMed Reports Second Quarter 2009 Financial Results

... ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, today reported financial results for the three and six...

EntreMed Reports First Quarter 2009 Financial Results

... ROCKVILLE, Md., May 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported financial res...

EntreMed Reports Fourth Quarter and Year-End 2008 Financial Results

... ROCKVILLE, Md., March 12 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for t...

EntreMed Focuses on Development of ENMD-2076

...agement Realigned to Provide Full Support for Clinical Activities ROCKVILLE, Md., Dec. 15 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company announced today plans to focus the Company's resources on its most promising near-term product candidate, E...

EntreMed Reports Clinical Program Progress and Company Update

... ROCKVILLE, Md., Nov. 12, /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, reported corporate and clini...

EntreMed to Present at the Rodman and Renshaw 10th Annual Healthcare Conference

... ROCKVILLE, Md., Nov. 7 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S....

EntreMed Teams with JSB-Partners to Expedite Partnering of its Aurora Kinase Program

... Additional Resources to Accelerate ENMD-2076 Partnering Efforts ROCKVILLE, Md., Aug. 12 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed to Present at the BIO 2008 Annual International Convention

... ROCKVILLE, Md., June 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S....

EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference

... ROCKVILLE, Md., May 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S....

Dr. Ronald E. Cape to Retire from EntreMed Board of Directors

... ROCKVILLE, Md., April 7, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the retireme...
ENMD in Medical Technology

Entremed Presents Results of ENMD-2076 Phase 1 Study in Advanced Cancer Patients

...ded Clinical Program Now Includes Solid and Hematological Malignancies ROCKVILLE, Md., June 1 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced the presentation of clinical data for i...

EntreMed Presents Initial Clinical Results for ENMD-2076

...ug Designation and Canadian CTA Accelerate ENMD-2076 Program Momentum ROCKVILLE, Md., Feb. 9 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced recent devel...

EntreMed Receives New Patent for 2-Methoxyestradiol Analogs

... Patent Covers Compositions and Methods ROCKVILLE, Md., June 11 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the issuance...

EntreMed Presents MKC-1 Phase 2 Data at American Society of Clinical Oncology Annual Meeting

... Antitumor Activity Demonstrated in Metastatic Breast Cancer Patients ROCKVILLE, Md., June 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presenta...

EntreMed Presents MKC-1 and ENMD-1198 Preclinical Data at AACR Annual Meeting

...pounds Demonstrate Potent Antitumor Activity in a Variety of Tumor Types ROCKVILLE, Md., April 16 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presenta...

EntreMed to Highlight ENMD-2076 Kinase Inhibitor at 2008 AACR Annual Meeting

...ral Presentation During the "New Drugs on the Horizon 2" Special Session ROCKVILLE, Md., April 11 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced it will pres...

EntreMed Achieves a Key Milestone Through Initiation of ENMD-2076 Clinical Program

...elective Kinase Inhibitor Phase 1 Trial in Advanced Cancer Patients ROCKVILLE, Md., April 9, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed Commences Continuous Dosing Clinical Trial For MKC-1

... Phase 1 Study to be Conducted in Advanced Cancer Patients ROCKVILLE, Md., April 2, 2008 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed Commences Phase 2 Study With MKC-1 in Ovarian/Endometrial Cancers

... Multi-Center Clinical Trial to be Conducted in Canada ROCKVILLE, Md., Jan. 23 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the commence...

EntreMed to Present at The New York Society of Security Analysts Industry Conference

... ROCKVILLE, Md., Dec. 5 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S....
ENMD in Biological Technology

EntreMed ENMD-2076 Phase 1 Data to Be Presented at ASCO Annual Meeting

...nical Program Adds Leukemia Clinical Study and Orphan Drug Designation ROCKVILLE, Md., May 15 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer today announced presentations for three of its clinical...

EntreMed Initiates ENMD-2076 Clinical Trial in Multiple Myeloma

... ROCKVILLE, Md., Dec. 9 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed to Present at the New York Society of Security Analysts Industry Conference

... ROCKVILLE, Md., Nov. 25 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that a Compa...

EntreMed's MKC-1 Meets Primary Efficacy Endpoint in Non-Small Cell Lung Cancer Clinical Trial

... Phase 2 Randomized Study Under Consideration ROCKVILLE, Md., Nov. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed Reports Third Quarter 2008 Financial Results

... ROCKVILLE, Md., Nov. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported results for t...

Antiangiogenic Role of 2ME2 Demonstrated in Rheumatoid Arthritis Models

... ROCKVILLE, Md., Nov. 3 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the publicat...

EntreMed's ENMD-2076 Demonstrates Tumor Regression in Human Colon Cancer Model

... ROCKVILLE, Md., Oct. 23 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced the presenta...

EntreMed to Present at BioPartnering Europe Conference

... ROCKVILLE, Md., Oct. 10 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that Thomas H...

EntreMed Announces Stock Listing Transfer to Nasdaq Capital Market

... ROCKVILLE, Md., Oct. 2 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today announced that it has ...

EntreMed Reports Second Quarter 2008 Financial Results

... EntreMed to Conduct Update Call on Tuesday, August 12, 2008 ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: enmd ), a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, today reported financial res...
Other Tags
(Date:10/20/2014)... Norristown, PA (PRWEB) October 20, 2014 ... of Matthew Voicheck as Assistant Director of their ... integral role in managing the innovative turnkey drug ... trials. , Matthew brings over 12 years of ... He joins Myoderm at the peak of their ...
(Date:10/20/2014)... October 20, 2014 Final Cut Pro X ... of the Citrus theme for FCPX filmmakers . , ... to describe the Citrus theme” Says Christina Austin, CEO of ... look so professional.” , Citrus comes with all the tools ... template are: four transitions for added style, a title screen ...
(Date:10/20/2014)... USA (PRWEB) October 20, 2014 Do ... track interventions? Here comes a wonderful app Metassessor for ... app development company helped its client “Intervention Development ... efficiently. The app is designed for iOS 4.3 or ... touch. This app is optimized for iPhone 5. It ...
(Date:10/19/2014)... 2014 This report provides comprehensive ... complete with comparative analysis at various stages, therapeutics ... route of administration (RoA) and molecule type, along ... releases. It also reviews key players involved in ... features on late-stage and discontinued projects. , Partial ...
(Date:10/19/2014)... Visual Impact Frequency Training - a ... to the public generating a frenzied buzz of ... community. The commotion surrounding the program's launch has ... an investigative review. , "Many gym-goers are familiar ... known as a training 'plateau' where they are ...
Breaking Medicine News(10 mins):Health News:Myoderm Hires Matthew Voicheck to Lead Turnkey Drug Sourcing Service 2Health News:Today Pixel Film Studios Announced the Release of the Citrus theme for Final Cut Pro X 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 2Health News:Metassessor App Launched: an RTI tool for Teachers & Parents 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2
(Date:10/15/2014)... is a non-traditional biophysics textbook and it describes how ... journey of discovery into biological systems and provides an ... It is about how our genes make proteins that ... of cells in an organism. It quantifies the principles ... can be found on both large and small scales. ...
(Date:10/15/2014)... the 44th Rosenstiel Award for Distinguished Work in Biomedical ... the mechanisms of genomic instability and its implications for ... second alumnus to win the Rosenstiel Award; the first, ... Alt is the Charles A. Janeway Professor of Pediatrics ... an investigator at the Howard Hughes Medical Institute at ...
(Date:10/14/2014)... fly genome for the first time, revealing robust immune ... thrives in pathogen-rich dung piles and garbage heaps. , ... Genome Biology , will increase understanding of house fly ... to resist insecticides, which could lead to novel control ... transmit more than 100 human and animal diseases, including ...
Breaking Biology News(10 mins):New book about life as seen from physics 2Brandeis awards 44th Rosenstiel Award to pioneering geneticist Fred Alt 2House fly genome reveals expanded immune system 2
Other Contents